An overview of the potential anticancer properties of cardamonin

• Main Authors: Shanaya Ramchandani, Irum Naz, Namrata Dhudha, Manoj Garg
• Format: Article
• Language: English
• Published: Open Exploration Publishing Inc. 2020-12-01
• Series: Exploration of Targeted Anti-tumor Therapy
• Subjects: cancer; cardamonin; chalcone; apoptosis; proliferation; wnt/β-catenin; nf-κb; pi3k/akt
• Online Access: https://www.explorationpub.com/Journals/etat/Article/100226

Cancer is one of the leading causes of mortality, contributing to 9.6 million deaths globally in 2018 alone. Although several cancer treatments exist, they are often associated with severe side effects and high toxicities, leaving room for significant advancements to be made in the field. In recent years, several phytochemicals from plants and natural bioresources have been extracted and tested against various human malignancies using both in vitro and in vivo preclinical model systems. Cardamonin, a chalcone extracted from the Alpinia species, is an example of a natural therapeutic agent that has anti-cancer and anti-inflammatory effects against human cancer cell lines, including breast, lung, colon, and gastric, in both in vitro culture systems as well as xenograft mouse models. Earlier, cardamonin was used as a natural medicine against stomach related issues, diarrhea, insulin resistance, nephroprotection against cisplatin treatment, vasorelaxant and antinociceptive. The compound is well-known to inhibit proliferation, migration, invasion, and induce apoptosis, through the involvement of Wnt/β-catenin, NF-κB, and PI3K/Akt pathways. The good biosafety and pharmacokinetic profiling of cardamonin satisfy it as an attractive molecule for the development of an anticancer agent. The present review has summarized the chemo-preventive ability of cardamonin as an anticancer agent against numerous human malignancies.